Novo Nordisk is rolling out a host of primary care tools to support pharmacy’s diabetes patients; identify people who may not have been diagnosed; and reduce the rates of people with the condition.
Novo Nordisk is upping its pharmacy focus in diabetes care to help stem the epidemic and improve patients’ medication adherence and persistence, Andrew Rolls, the company’s senior product manager, endocrine, told an industry briefing in Sydney.
“Diabetes is only identified in half of the population and only half of those people are treated; Novo Nordisk is trying to change that,” says Rolls.
The company is one of the largest suppliers of insulin and has been involved in world diabetes care since it began the production of insulin in the early 1920s.
“We are am scientific company by nature and our proud of our ethical values and this means we feel we are moving towards furthering our partnership with pharmacy in primary care.
“Pharmacy’s role is to changing and we want to respond to that,” says Rolls.
He says a collaborative approach is needed and “pharmacy’s role is critical as part of a multidisciplinary team” involving GPs and independent diabetes nurses.
“We are just putting our toe in the water but want to grow our focus further to reduce the rates of diabetes.”
He says the company believes it could support pharmacy to implement and optimise programs in the 6CPA. Additionally, there are new areas of collaboration, especially in diabetes screening or identifying patients who have pre-diabetes.
Novo Nordisk will roll out a suite of tools to support pharmacy and its diabetes offer.
“Seventy per cent of our focus is on diabetes, so we are very well placed to develop extra resources to support pharmacy in this area,” added Andrew.
Pharmacy also has the advantage that it can offer lifestyle and weight management support programs to help prevent the onset of diabetes, attendees were told.
The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Also, to maximise its support of primary’s increasing role in the primary care sphere, Novo Nordisk is working with the pharmaceutical arm of Sinapse. Sinapse offers the pharmaceutical industry a range of tools and services including sales and marketing strategies, IT, business systems, and product distribution. Its senior health strategist is former Pharmacy Guild president, Kos Sclavos.